

[OJ41] 一般演題口述 (日本語) 41
Thromboembolism/Antithrombotic Therapy/Thrombolysis 1

2015 年 4 月 26 日 (日) 10:40-12:10 第 24 会場 (グランフロント大阪 北館 タワー C 8 階 ナレッジキャピタル カンファレンスルーム C01 + 02)

座長: Yukihiro Koretsune (国立病院機構大阪医療センター 臨床研究センター)
座長: Toshiaki Izumi (田附興風会医学研究所北野病院 心臓センター)

OJ-243

A Study of Safety and Efficacy of Anticoagulant Therapy in the Treatment of Atrial Fibrillation in Kanagawa (ASSAF-K)

Tomoyuki Kunishima¹, Yutaka Hatori¹, Hiroyuki Sakai¹, Kazuhiko Mitani¹, Keiichi Chin¹, Nobuo Hatori¹, Naoki Sato¹

1: CVDCC Scientific Committee, Kanagawa

Background The atrial fibrillation (AF) increases with aging, and the risk of cerebral infarction (CI). Oral anticoagulants (OAC) are necessary for CI prevention due to the AF. In the guidelines for pharmacotherapy of AF (JCS 2013), the anticoagulant therapy is recommended for patients with CHADS2 score > 2. This study was aimed at whether treatment of adequate anticoagulants was done for patients with AF in the novel oral anticoagulants (NOAC) era. **Method** ASSAF-K is a prospective study of the temporary or persistent AF patients. A total 82 institutions (22 Hospitals and 60 clinics) participated in registration. The enrollment of patients started in September 2013. We examined patient's background, presence of the medical treatment, CHADS2 score, CHA2DS2-VASc score, HAS-BLED score and the presence of the major complication. **Results** By March 2014, a total 3311 patients was enrolled. The clinic patients were significantly higher than the hospital patients in CHADS2 score (1.7 vs 2.0; p < 0.01), CHA2DS2-VASc score (2.8 vs 3.2; p < 0.01), HAS-BLED score (2.1 vs 2.5; p < 0.01) were significantly higher at the clinic patients than the hospital patients. Patients with CHA2DS2-VASc > 2 were significantly higher than patients with CHADS2 > 2 in both hospitals (77.7% vs 51.6%; p < 0.01) and clinics (85.7% vs 60.0%; p < 0.01). **Conclusion** More patients needed anticoagulant therapy in clinics than hospitals. We had the need to shift to risk evaluation of the anticoagulant therapy immediately using CHA2DS2-VASc in Japan.

[Keywords] atrial fibrillation / anticoagulants